American BriVision teams up with BioLite Japan
Collaboration combines early-stage discovery capabilities with clinical trial expertise
FREMONT, Calif.—American BriVision Corp., a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system and ophthalmology, recently announced an exclusive, worldwide, multitarget research collaboration and license agreement with BioLite Japan, a drug discovery and research firm based in Japan that seeks to identify early-stage opportunities in drug development, digital health and medical device technology for further development.
Under the terms of the agreement, BioLite Japan will identify new chemical entities, new biological entities, diagnostic tools and biomarkers—among other things—in the early stages of discovery and development, and will conduct in-licensing and preclinical research as necessary. BioLite Japan will then transfer the rights of such candidates to American BriVision for further clinical development, regulatory approvals and subsequent commercialization in exchange for product royalties and/or milestone payments.
“We are extremely excited to be working with BioLite Japan in this translational research joint venture and gaining access to additional early-stage product candidates that we otherwise would not have access to,” said Dr. Howard Doong, CEO of American BriVision. “The team at BioLite Japan has extensive experience and distinguished careers in the academic, medical, and business fields, primarily in Japan and Asia, all of which will be critical in identifying the proper early-stage opportunities for our partnership to pursue. Additionally, we look forward to gaining additional exposure to the Japanese capital markets, as we look to expand beyond our markets in Taiwan and the U.S. in the hopes of diversifying our investor base.”
